In today’s briefing:
- Bukalapak (BUKA IJ) – Higher Take Rates and Better Quality Growth Ahead
- Indiamart Intermesh Ltd: Q4-F2022 Result Update
- AbbVie (ABBV US): Mixed Q1 Show; 2022 Guidance Trimmed; Stock Price Reaction Seems Overdone
- Global Cord Blood (CO US): Fate Seems to Be Changing as New Growth Engine Added
Bukalapak (BUKA IJ) – Higher Take Rates and Better Quality Growth Ahead
- Bukalapak (BUKA IJ) 1Q2022 results were all about execution, with significant improvements in take-rates for its Mitra business, and even more so for its marketplace segment.
- The launch of AlloFresh and Allo Bank Indonesia will add some further depth and breadth to the platform’s product offering and help to accerlate the move towards profitabilty.
- Bukalapak (BUKA IJ) looks like an increasingly interesting way to play the Indonesian digital economy with an expanding ecosystem and increasing take-rates at the same time.
Indiamart Intermesh Ltd: Q4-F2022 Result Update
- Growth in number of subscribers on the back of increased workforce, it may be temporary spike
- Cost pressure visible as per our expectation and the margins continue to be at lower level on Y-o-Y basis
- Buyback of shares within a year of QIP meets more than the eye
AbbVie (ABBV US): Mixed Q1 Show; 2022 Guidance Trimmed; Stock Price Reaction Seems Overdone
- Abbvie Inc (ABBV US) reported mixed results in Q1 2022. While revenue of $13.538 billion missed consensus by $70 million, adjusted EPS of 3.16 beat consensus of $3.14.
- Q1 revenue from immunology portfolio was $6.141 billion, up 6.9% y/y. Management is still confident of delivering $15 billion combined revenue from Rinvoq and Skyrizi by 2025.
- The company has reduced 2022 adjusted EPS guidance to $13.92–14.12 from $14.00–14.20, to reflect an unfavorable impact related to acquired IPR&D and milestones expenses incurred during Q1.
Global Cord Blood (CO US): Fate Seems to Be Changing as New Growth Engine Added
- Global Cord Blood (CO US) is foraying into multi-billion-dollar cell therapy space through acquisition of privately-held clinical-stage biotechnology company, Cellenkos.
- Cellenkos utilizes umbilical cord blood as the raw material to develop T-regulatory cell therapies for treating autoimmune diseases and inflammatory disorders.
- Global Cord believes that Cellenkos is a perfect fit for the company and that its products can have distinct synergies with the company’s existing line of business.
Related tickers: Abbvie Inc (ABBV.N), Global Cord Blood (CO.N)
Before it’s here, it’s on Smartkarma
